Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization

Michelle F. Huffaker, Anne Y. Liu, Gregory M. Enns, Suresh Vijay, Antonio J. Amor, N. Franklin Adkinson

Research output: Contribution to journalArticlepeer-review

Abstract

Allergic immune-mediated hypersensitivity reactions are known potential complications of enzyme replacement therapy. Sebelipase alfa, recombinant lysosomal acid lipase (LAL), is a potentially life-altering treatment for patients with LAL deficiency. There is very little information on the diagnosis and management of immediate hypersensitivity reactions to this drug. Here we present three unique cases of hypersensitivity reactions to sebelipase alfa, spanning a broad age spectrum from infancy to adulthood, each managed with successful rapid desensitization.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalJIMD Reports
Volume49
Issue number1
DOIs
StatePublished - Jun 1 2019
Externally publishedYes

Keywords

  • allergy
  • anaphylaxis
  • desensitization
  • enzyme replacement therapy
  • hypersensitivity
  • sebelipase alfa

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)

Fingerprint Dive into the research topics of 'Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization'. Together they form a unique fingerprint.

Cite this